Literature DB >> 22445578

Effectiveness of percutaneous coronary intervention in patients with silent myocardial ischemia (post hoc analysis of the COURAGE trial).

Gilbert Gosselin1, Koon K Teo, Jean-Francois Tanguay, Rohit Gokhale, Pamela M Hartigan, David J Maron, Vipul Gupta, G B John Mancini, Eric R Bates, Bernard R Chaitman, John A Spertus, William J Kostuk, Marcin Dada, Steven P Sedlis, Daniel S Berman, Leslee J Shaw, Robert A O'Rourke, William S Weintraub, William E Boden.   

Abstract

Previous studies have suggested that percutaneous coronary intervention (PCI) decreases long-term mortality in patients with silent myocardial ischemia (SMI), but whether PCI specifically decreases mortality when added to intensive medical therapy is unknown. We performed a post hoc analysis of clinical outcomes in patients in the COURAGE trial based on the presence or absence of anginal symptoms at baseline. Asymptomatic patients were classified as having SMI by electrocardiographic ischemia at rest or reversible stress perfusion imaging (exercise-induced or pharmacologic). Study end points included the composite primary end point (death or myocardial infarction [MI]); individual end points of death, MI, and hospitalization for acute coronary syndrome; and need for revascularization. Of 2,280 patients 12% (n = 283) had SMI and 88% were symptomatic (n = 1,997). There were no between-group differences in age, gender, cardiac risk factors, previous MI or revascularization, extent of angiographic disease, or ischemia by electrocardiogram or imaging. Compared to symptomatic patients, those with SMI had fewer subsequent revascularizations (16% vs 27%, p <0.001) regardless of treatment assignment and fewer hospitalizations for acute coronary syndrome (7% vs 12%, p <0.04). No significant differences in outcomes were observed between the 2 treatment groups, although there was a trend toward fewer deaths in the PCI group (n = 7, 5%) compared to the optimal medical therapy (OMT) group (n = 16, 11%, p = 0.12). In conclusion, addition of PCI to OMT did not decrease nonfatal cardiac events in patients with SMI but showed a trend toward fewer deaths. Although underpowered, given similar outcomes in other small studies, these findings suggest the need for an adequately powered trial of revascularization versus OMT in SMI patients. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22445578     DOI: 10.1016/j.amjcard.2011.11.023

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Higher coronary artery calcification score is associated with adverse prognosis in patients with stable angina pectoris.

Authors:  Renrong Wang; Xiaoxiao Liu; Chunxia Wang; Xinhe Ye; Xin Xu; Chengjian Yang
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Revascularization for silent ischemia?: another piece of the puzzle.

Authors:  David J Maron; Judith S Hochman
Journal:  J Am Coll Cardiol       Date:  2013-04-16       Impact factor: 24.094

3.  Angiographic Complete versus Clinical Selective Incomplete Percutaneous Revascularization in Heart Failure Patients with Multivessel Coronary Disease.

Authors:  Chieh-Yu Chang; Chun-Chi Chen; I-Chang Hsieh; Ming-Jer Hsieh; Cheng-Hung Lee; Dong-Yi Chen; Ming-Lung Tsai; Ming-Yun Ho; Jih-Kai Yeh; Yu-Chang Huang; Yu-Ying Lu; Chao-Yung Wang; Shang-Hung Chang; Ming-Shien Wen
Journal:  J Interv Cardiol       Date:  2020-07-27       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.